BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31093891)

  • 21. Potential using of microRNA-34A in combination with paclitaxel in colorectal cancer cells.
    Soltani-Sedeh H; Irani S; Mirfakhraie R; Soleimani M
    J Cancer Res Ther; 2019; 15(1):32-37. PubMed ID: 30880751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer.
    Wen D; Peng Y; Lin F; Singh RK; Mahato RI
    Cancer Res; 2017 Jun; 77(12):3244-3254. PubMed ID: 28428276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo.
    Chen S; Zhang Z; Zhang J
    Drug Des Devel Ther; 2019; 13():1145-1153. PubMed ID: 31114158
    [No Abstract]   [Full Text] [Related]  

  • 24. Polymeric Hybrid Nanomicelles for Cancer Theranostics: An Efficient and Precise Anticancer Strategy for the Codelivery of Doxorubicin/miR-34a and Magnetic Resonance Imaging.
    Xie X; Chen Y; Chen Z; Feng Y; Wang J; Li T; Li S; Qin X; Wu C; Zheng C; Zhu J; You F; Liu Y; Yang H
    ACS Appl Mater Interfaces; 2019 Nov; 11(47):43865-43878. PubMed ID: 31684723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Ultrasound Contrast Agents for the Enhancement of Tumor Diagnosis and Tumor Therapy.
    Moon H; Yoon C; Lee TW; Ha KS; Chang JH; Song TK; Kim K; Kim H
    J Biomed Nanotechnol; 2015 Jul; 11(7):1183-92. PubMed ID: 26307841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HeLa Cell-Derived Paclitaxel-Loaded Microparticles Efficiently Inhibit the Growth of Cervical Carcinoma.
    Peng J; Zhao J; Zhao Y; Wu P; Gou L; Fu S; Chen P; Lu Y; Yang L
    Int J Nanomedicine; 2020; 15():6409-6420. PubMed ID: 32922008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preparation Of Nanobubbles Modified With A Small-Molecule CXCR4 Antagonist For Targeted Drug Delivery To Tumors And Enhanced Ultrasound Molecular Imaging.
    Peng Y; Zhu L; Wang L; Liu Y; Fang K; Lan M; Shen D; Liu D; Yu Z; Guo Y
    Int J Nanomedicine; 2019; 14():9139-9157. PubMed ID: 32063704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymeric Nanomedicine for Combined Gene/Chemotherapy Elicits Enhanced Tumor Suppression.
    Xu B; Xia S; Wang F; Jin Q; Yu T; He L; Chen Y; Liu Y; Li S; Tan X; Ren K; Yao S; Zeng J; Song X
    Mol Pharm; 2016 Feb; 13(2):663-76. PubMed ID: 26695934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic ultrasonic microbubbles carrying paclitaxel and LyP-1 peptide: preparation, characterization and application to ultrasound-assisted chemotherapy in breast cancer cells.
    Yan F; Li X; Jin Q; Jiang C; Zhang Z; Ling T; Qiu B; Zheng H
    Ultrasound Med Biol; 2011 May; 37(5):768-79. PubMed ID: 21458148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JD enhances the anti-tumour effects of low-dose paclitaxel on gastric cancer MKN45 cells both in vitro and in vivo.
    Wang C; Wang R; Zhou K; Wang S; Wang J; Shi H; Dou Y; Yang D; Chang L; Shi X; Liu Y; Xu X; Zhang X; Ke Y; Liu H
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):971-982. PubMed ID: 27620208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-21 inhibitor suppresses cell proliferation and colony formation through regulating the PTEN/AKT pathway and improves paclitaxel sensitivity in cervical cancer cells.
    Du G; Cao D; Meng L
    Mol Med Rep; 2017 May; 15(5):2713-2719. PubMed ID: 28447761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR.
    Zhang B; Zhao R; He Y; Fu X; Fu L; Zhu Z; Fu L; Dong JT
    Oncotarget; 2016 Feb; 7(5):5702-14. PubMed ID: 26744318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paclitaxel-liposome-microbubble complexes as ultrasound-triggered therapeutic drug delivery carriers.
    Yan F; Li L; Deng Z; Jin Q; Chen J; Yang W; Yeh CK; Wu J; Shandas R; Liu X; Zheng H
    J Control Release; 2013 Mar; 166(3):246-55. PubMed ID: 23306023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer.
    Parayath NN; Gandham SK; Leslie F; Amiji MM
    Cancer Lett; 2019 Oct; 461():1-9. PubMed ID: 31288064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
    Zheng P; Dong L; Zhang B; Dai J; Zhang Y; Wang Y; Qin S
    Histochem Cell Biol; 2019 Oct; 152(4):281-291. PubMed ID: 31352515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study of the UTMD-based delivery system to induce cervical cancer cell apoptosis and inhibit proliferation with shRNA targeting Survivin.
    Chen ZY; Liang K; Lin Y; Yang F
    Int J Mol Sci; 2013 Jan; 14(1):1763-77. PubMed ID: 23325045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer.
    Shen Y; Wang P; Li Y; Ye F; Wang F; Wan X; Cheng X; Lu W; Xie X
    Br J Cancer; 2013 Jul; 109(1):92-9. PubMed ID: 23778521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.
    Zhao Y; Tu MJ; Yu YF; Wang WP; Chen QX; Qiu JX; Yu AX; Yu AM
    Biochem Pharmacol; 2015 Dec; 98(4):602-13. PubMed ID: 26518752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-34a Inhibits Viability and Invasion of Human Papillomavirus-Positive Cervical Cancer Cells by Targeting E2F3 and Regulating Survivin.
    Geng D; Song X; Ning F; Song Q; Yin H
    Int J Gynecol Cancer; 2015 May; 25(4):707-13. PubMed ID: 25675046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance.
    Jin X; Mo R; Ding Y; Zheng W; Zhang C
    Mol Pharm; 2014 Jan; 11(1):145-57. PubMed ID: 24261922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.